Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
China
Fujian Cancer Hospital, Fuzhou, Fujian Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Henan Cancer Hospital, Zhengzhou, Henan Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai Municipality West China Second University Hospital,Sichuan University, Chengdu, Sichuan